Company intelligence / Profile preview

Rokote Laboratories Finland

Kuopio and Helsinki, Finlandrokote.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Developing FINCoVac 2.1, an intranasal COVID-19 vaccine that aims to elicit a strong mucosal immune response in nasopharyngeal cells. The vaccine consists of an adenoviral vector with the SARS-CoV-2 spike protein gene. As of August 2024, the company signed an agreement with 3PBIOVIAN for GMP manufacturing to bring the vaccine into Phase I clinical studies.

Therapeutic areas: Infectious Diseases
Modalities: Adenoviral vector vaccines
Industry: Biotech

Drug pipeline

6 assets

FINCoVac

5 more assets in the full pipeline.

Partnerships

3PBIOVIAN (manufacturing partner)

Beyond the preview

Go deeper on Rokote Laboratories Finland.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rokote Laboratories Finland.